Bicocca Open Archive

Logo unimib boa
GAMBACORTI PASSERINI, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.168
EU - Europa 12.433
AS - Asia 6.518
SA - Sud America 346
AF - Africa 58
Continente sconosciuto - Info sul continente non disponibili 34
OC - Oceania 20
Totale 46.577
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.725
IT - Italia 2.806
SG - Singapore 2.708
DE - Germania 2.316
CN - Cina 1.791
IE - Irlanda 1.762
SE - Svezia 1.589
RU - Federazione Russa 1.212
HK - Hong Kong 1.036
UA - Ucraina 1.013
GB - Regno Unito 563
CA - Canada 425
FI - Finlandia 299
BR - Brasile 274
ID - Indonesia 234
TR - Turchia 193
VN - Vietnam 188
FR - Francia 175
IN - India 172
DK - Danimarca 119
AT - Austria 108
BE - Belgio 101
NL - Olanda 98
PL - Polonia 60
BG - Bulgaria 32
EU - Europa 32
JP - Giappone 32
IR - Iran 30
CZ - Repubblica Ceca 27
KR - Corea 23
RO - Romania 22
ES - Italia 21
AR - Argentina 20
CH - Svizzera 20
LT - Lituania 15
AU - Australia 14
GR - Grecia 14
EG - Egitto 13
NO - Norvegia 13
PE - Perù 13
PT - Portogallo 13
CL - Cile 10
EC - Ecuador 10
KG - Kirghizistan 10
MU - Mauritius 10
MX - Messico 10
BD - Bangladesh 9
CO - Colombia 9
PH - Filippine 9
PK - Pakistan 9
MY - Malesia 8
MA - Marocco 7
TN - Tunisia 7
IQ - Iraq 6
NZ - Nuova Zelanda 6
RS - Serbia 6
ZA - Sudafrica 6
AM - Armenia 5
AZ - Azerbaigian 5
EE - Estonia 5
IL - Israele 5
LV - Lettonia 5
SC - Seychelles 5
TH - Thailandia 5
UZ - Uzbekistan 5
JO - Giordania 4
LA - Repubblica Popolare Democratica del Laos 4
SK - Slovacchia (Repubblica Slovacca) 4
BO - Bolivia 3
KE - Kenya 3
KZ - Kazakistan 3
LK - Sri Lanka 3
MD - Moldavia 3
PY - Paraguay 3
SA - Arabia Saudita 3
TW - Taiwan 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AL - Albania 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
CY - Cipro 2
HR - Croazia 2
KW - Kuwait 2
LU - Lussemburgo 2
MK - Macedonia 2
NG - Nigeria 2
NI - Nicaragua 2
PA - Panama 2
SN - Senegal 2
BA - Bosnia-Erzegovina 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GE - Georgia 1
HN - Honduras 1
KH - Cambogia 1
LB - Libano 1
MZ - Mozambico 1
Totale 46.569
Salva come PNG Salva come JPEG
Città #
Ann Arbor 6.174
Woodbridge 2.706
Fairfield 2.295
Singapore 1.739
Dublin 1.718
Houston 1.601
Chandler 1.489
Frankfurt am Main 1.438
Ashburn 1.350
Wilmington 1.313
Milan 1.158
Jacksonville 1.040
Hong Kong 1.024
Seattle 928
Dearborn 794
Cambridge 784
Santa Clara 687
New York 660
Princeton 564
Nanjing 315
Shanghai 270
Altamura 249
Lawrence 249
Beijing 225
Jakarta 225
Göttingen 188
Lachine 173
San Diego 137
Boardman 127
Guangzhou 124
Toronto 103
Helsinki 101
Lissone 101
Andover 98
Brussels 97
Nanchang 95
Dong Ket 91
Ottawa 90
Shenyang 89
Council Bluffs 80
Fremont 80
Nuremberg 79
Los Angeles 76
Vienna 76
Hebei 68
Tianjin 67
Fürstenwalde 65
Romola 62
Munich 61
Jiaxing 56
London 54
Rome 53
Lodz 52
Jinan 49
Falls Church 48
Norwalk 46
Kocaeli 45
Changsha 44
Kunming 42
Mountain View 42
Pune 41
Chicago 38
Redmond 37
Edmonton 35
Hangzhou 32
Huizen 31
Washington 30
Hefei 28
Cinisello Balsamo 27
Monza 27
Kiev 26
Zhengzhou 25
Turin 24
Dallas 23
Moscow 22
Ningbo 21
São Paulo 21
Plovdiv 20
Bologna 19
Bonndorf 19
Carate Brianza 19
Desio 19
Pavia 18
Como 17
Bari 16
Detroit 16
Kilburn 16
Nürnberg 16
San Mateo 16
St Petersburg 15
Buffalo 14
Leawood 14
Sacramento 14
Brno 13
Lappeenranta 13
Monmouth Junction 13
Taizhou 13
University Park 13
Daejeon 12
Fuzhou 12
Totale 34.699
Salva come PNG Salva come JPEG
Nome #
Characterization of intra-host SARS-CoV-2 variants improves phylogenomic reconstruction and may reveal functionally convergent mutations 427
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 413
A bioinformatics procedure to identify and annotate somatic mutations in whole-exome sequencing data 371
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 367
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 367
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 333
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 328
Acute myeloid leukaemia niche regulates response to L-asparaginase 324
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 320
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 317
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 313
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene 313
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 309
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 301
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis 296
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes 294
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 283
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 282
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 282
WHOLE-EXOME SEQUENCING OF A PHILADELPHIA NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENT THROUGH THE EXON-CAPTURE TECHNIQUE 281
A computational procedure to identify and annotate somatic mutations in next-generation sequencing data 280
Imatinib long term effects study: three years of follow-up and assessment 274
Chronic myeloid leukemia: Second-line drugs of choice 274
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 274
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 274
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 273
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 271
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 270
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 268
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 256
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 252
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 241
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 236
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 235
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 233
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 225
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 222
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 222
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 222
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 221
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 217
BCR-ABL nuclear entrapment kills human CML cells: Ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B 215
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al 215
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy 213
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 213
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 213
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 213
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 212
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia 209
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 208
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 207
Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients 205
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 205
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 205
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 204
ALK inhibitors for clinical use in cancer therapy 201
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 201
Erratum: Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design (Journal of Medicinal Chemistry (2017) 60:22 (9205-9221) DOI: 10.1021/acs.jmedchem.7b01039) 200
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 200
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 200
Reply to P. Laneuville et al 199
A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation 199
Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment 198
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 197
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 197
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 196
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias 195
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 194
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 193
Inhibition of RET tyrosine kinase by SU5416 193
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 191
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY 191
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib 186
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 186
Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia 185
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 185
Expression, purification, and inhibition of human RET tyrosine kinase 184
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 183
Whole-Exome Sequencing Data - Identifying Somatic Mutations 183
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 182
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 182
CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis 181
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 180
Dissection of the RET/ß-catenin interaction in the TPC1 thyroid cancer cell line 178
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 176
Differences among young adults, adults and elderly chronic myeloid leukemia patients 175
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making 174
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years 174
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study) 174
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 173
The ALK gene, an attractive target for inhibitor development 173
FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery 173
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 173
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 172
BCR AND BCR-ABL REGULATION DURING MYELOID DIFFERENTIATION IN HEALTHY DONORS AND CHRONIC PHASE-BLAST CRISIS CML PATIENTS 172
ABL INHIBITOR BMS354825 BINDING MODE IN ABELSON KINASE REVEALED BY MOLECULAR DOCKING STUDIES 172
Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia 171
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis 171
Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis 171
Increased sFLT-1/PlGF ratio in COVID-19: A novel link to angiotensin II-mediated endothelial dysfunction 171
Totale 23.003
Salva come PNG Salva come JPEG
Categoria #
all - tutte 173.897
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 173.897
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.134 0 0 0 0 0 0 0 0 0 474 492 168
2020/20217.402 336 311 901 756 605 687 780 698 650 650 473 555
2021/20224.093 331 406 499 279 276 366 213 228 206 304 329 656
2022/20236.561 864 1.919 566 554 469 932 72 333 418 126 152 156
2023/20245.361 129 146 202 235 671 1.456 978 159 443 287 90 565
2024/20257.918 790 1.498 734 665 1.115 506 914 419 1.112 165 0 0
Totale 48.368